Glimep Adverse Reactions

Hypoglycemia: As a result of blood glucose-lowering action of glimepiride, hypoglycemia may occur, which, based on what is known of other sulfonylureas, may also be prolonged.
Possible symptoms of hypoglycemia include headache, ravenous hunger, nausea, vomiting, lassitude, sleepiness, disordered sleep, restlessness, aggressiveness, impaired concentration, impaired alertness and reactions, depression, confusion, speech disorders, aphasia, visual disorder, tremor, pareses, sensory disturbances, dizziness, helplessness, loss of self-control, delirium, cerebral convulsion, somnolence and loss of consciousness up to and including coma, shallow, respiration and bradycardia.
In addition, signs of adrenergic counter-regulation may be present eg, sweating, clammy skin, anxiety, tachycardia, hypertension, palpitation, angina pectoris and cardiac arrhythmias.
Eyes: Especially at the start of treatment, there may be temporary visual impairment due to the change in blood glucose levels.
The cause is a temporary alteration in the turgidity and hence, the refractive index of the lens, this being dependent on blood glucose level.
Digestive Tract: Occasionally, gastrointestinal symptoms eg, nausea, vomiting, sensation of pressure or fullness in the epigastrium, abdominal pain, and diarrhea may occur.
In rare cases, there may be elevation of liver enzyme levels. Sulfonylureas, including glimepiride, may also, in isolated instances, cause impairment of liver function (eg, with cholestasis and jaundice) as well as hepatitis which may also lead to liver failure.
Blood: Changes in the blood picture may occur: Rarely, thrombopenia and, in isolated cases, leucopenia may develop. Based on what is known to other sulfonylureas, drugs of this class may, in isolated instances, cause in addition to the previously mentioned hemolytic anemia or eg, erythrocytopenia, granulocytopenia, agranulocytosis and (eg, due to myelosuppression) pancytopenia.
Others: Occasionally, allergic or pseudoallergic reactions may occur eg, in the form of itching, urticaria or rashes. Based on what is known of other sulfonylureas, such mild reactions may develop into serious reactions with dyspnea and a fall in blood pressure, sometimes progressing to shock. In the event of urticaria, a physician must therefore be notified immediately.
In isolated cases, a decrease in serum sodium concentration and, based on what is known of other sulfonylureas, allergic vasculitis or hypersensitivity of the skin to light may occur.